Abstract |
Breast cancer is a heterogeneous disease and new clinical markers are needed to individualise disease management and therapy further. Alterations in the PI3K/AKT pathway, mainly PIK3CA mutations, have been shown frequently especially in the luminal breast cancer subtypes, suggesting a cross-talk between ER and PI3K/AKT. Aberrant PI3K/AKT signalling has been connected to poor response to anti-oestrogen therapies. In vitro studies have shown protein tyrosine phosphatase, non-receptor type 2 (PTPN2) as a previously unknown negative regulator of the PI3K/AKT pathway. Here, we evaluate possible genomic alterations in the PTPN2 gene and its potential as a new prognostic and treatment predictive marker for endocrine therapy benefit in breast cancer. PTPN2 gene copy number was assessed by real-time PCR in 215 tumour samples from a treatment randomised study consisting of postmenopausal patients diagnosed with stage II breast cancer 1976-1990. Corresponding mRNA expression levels of PTPN2 were evaluated in 86 available samples by the same methodology. Gene copy loss of PTPN2 was detected in 16% (34/215) of the tumours and this was significantly correlated with lower levels of PTPN2 mRNA. PTPN2 gene loss and lower mRNA levels were associated with activation of AKT and a poor prognosis. Furthermore, PTPN2 gene loss was a significant predictive marker of poor benefit from tamoxifen treatment. In conclusion, genomic loss of PTPN2 may be a previously unknown mechanism of PI3K/AKT upregulation in breast cancer. PTPN2 status is a potential new clinical marker of endocrine treatment benefit which could guide further individualised therapies in breast cancer.
|
Authors | Elin Karlsson, Cynthia Veenstra, Shad Emin, Chhanda Dutta, Gizeh Pérez-Tenorio, Bo Nordenskjöld, Tommy Fornander, Olle Stål |
Journal | Breast cancer research and treatment
(Breast Cancer Res Treat)
Vol. 153
Issue 1
Pg. 31-40
(Aug 2015)
ISSN: 1573-7217 [Electronic] Netherlands |
PMID | 26208487
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents, Hormonal
- Biomarkers, Tumor
- RNA, Messenger
- Tamoxifen
- Proto-Oncogene Proteins c-akt
- Protein Tyrosine Phosphatase, Non-Receptor Type 2
|
Topics |
- Antineoplastic Agents, Hormonal
(pharmacology, therapeutic use)
- Biomarkers, Tumor
- Breast Neoplasms
(drug therapy, genetics, metabolism, mortality, pathology)
- Drug Resistance, Neoplasm
(genetics)
- Female
- Gene Deletion
- Gene Dosage
- Gene Expression
- Humans
- Lymphatic Metastasis
- Prognosis
- Protein Tyrosine Phosphatase, Non-Receptor Type 2
(deficiency, genetics)
- Proto-Oncogene Proteins c-akt
(metabolism)
- RNA, Messenger
(genetics)
- Survival Analysis
- Tamoxifen
(pharmacology, therapeutic use)
- Tumor Burden
|